Registration Open: Paying for Cures Workshop
March 10 at MIT
Survey the financial challenges of sustaining new cell and gene therapies, assess adoption barriers, and anticipate coming changes in practice and policy. Special focus on challenges and solutions for private and public healthcare payers.
Now Open: The Paying for Cures Toolkit is now online
The free online resource helps payers, patient advocates, drug developers, policymakers, and other healthcare system stakeholders explore strategies to sustainably finance new cell and gene therapies with durable—and potentially curative—effects. Read the press release announcement
New Research: FDA Communication Guidelines
This brief explores some of the possible impacts of FDA regulations on the use of metrics in performance-based agreements.
FoCUS in the Media
Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies
Pharmaceutical Executive, January 9, 2020
By Jane Barlow, Matt Courtney, and Mark Trusheim
This article compares findings from two FoCUS surveys, between 2017 and 2019, regarding US healthcare payers’ awareness, concern, and ideas on potential solutions for implementing cell and gene therapies.
FoCUS in the Community
On January 23, Mark Trusheim presented at Pfizer in New York City, and on January 29 he will participate in the MassBio Policy Breakfast in Boston.
The next FoCUS Design Lab will be held April 28–30 in Boston. Invitation only